- Home
- MOB vs KALA Comparison
MOB vs KALA Comparison
Compare MOB & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOB
- KALA
- Stock Information
- Founded
- MOB 2008
- KALA 2009
- Country
- MOB Israel
- KALA United States
- Employees
- MOB N/A
- KALA N/A
- Industry
- MOB Real Estate Investment Trusts
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- MOB Real Estate
- KALA Health Care
- Exchange
- MOB Nasdaq
- KALA Nasdaq
- Market Cap
- MOB 24.1M
- KALA 26.2M
- IPO Year
- MOB 2022
- KALA 2017
- Fundamental
- Price
- MOB $6.50
- KALA $14.56
- Analyst Decision
- MOB Strong Buy
- KALA Strong Buy
- Analyst Count
- MOB 1
- KALA 2
- Target Price
- MOB $10.00
- KALA $13.50
- AVG Volume (30 Days)
- MOB 542.4K
- KALA 205.1K
- Earning Date
- MOB 08-12-2025
- KALA 08-08-2025
- Dividend Yield
- MOB N/A
- KALA N/A
- EPS Growth
- MOB N/A
- KALA N/A
- EPS
- MOB N/A
- KALA N/A
- Revenue
- MOB $2,826,361.00
- KALA N/A
- Revenue This Year
- MOB N/A
- KALA N/A
- Revenue Next Year
- MOB N/A
- KALA N/A
- P/E Ratio
- MOB N/A
- KALA N/A
- Revenue Growth
- MOB N/A
- KALA N/A
- 52 Week Low
- MOB $0.85
- KALA $2.92
- 52 Week High
- MOB $6.60
- KALA $15.80
- Technical
- Relative Strength Index (RSI)
- MOB 69.59
- KALA 81.56
- Support Level
- MOB $5.30
- KALA $8.50
- Resistance Level
- MOB $6.60
- KALA $15.80
- Average True Range (ATR)
- MOB 0.70
- KALA 1.25
- MACD
- MOB 0.09
- KALA 0.53
- Stochastic Oscillator
- MOB 90.10
- KALA 83.50
About MOB Mobilicom Limited
Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers. Its products include OS3 Platform Software, ICE Cybersecurity Software, MCU Mesh Networking, SkyHopper Datalinks, Mobile Ground Control Stations and System Engineering Services.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.